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Background: Hepatitis B infection is a major public health problem worldwide. Given that immune response towards the vaccine is not 
perfect, we aimed to evaluate circumstances of immune response in vaccinated students. 
Materials and Methods: In this study, 219 medical students of Ardabil University of Medical Sciences were recruited, who had been 
administered vaccine series for the first time, and booster doses after one and six months completely. The serum samples were extracted from 
whole blood of the participants. The concentration of Hepatitis B surface antigen (HBsAg) and anti-HBs antibody (HBsAb) was measured 
using a commercial ELISA kit. 
Results: It was observed that 201 cases (91.8%) out of 219 cases had positive anti-HBs antibody response, and 18 subjects (8.2%) were 
nonresponsive cases. Level of HBsAb was significantly different between males and females as well as alcoholics and non-alcoholics. None 
of the cases was identified as positive for HBsAg. 
Conclusion: Considering the results of the present and previous studies in other countries, it can be claimed that the mass vaccination has 
been effective, especially in medical students. 
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1. Background 
HBV  is  a  DNA  virus  and  a  member  of  Hepadnaviridae 
family. Humans are known as natural hosts for HBV which 
enters to the liver and crosses through the bloodstream, and its 
replication occurs only in liver cells (1).The World Health 
Organization (WHO) has reported that approximately 2 billion 
people in the world have been contaminated with HBV, and 
about 350 million people suffer from HBV-induced chronic 
liver disease (2). More than 3% of the general population is 
affected in Iran, among them 200,000-300,000 cases have 
chronic hepatitis. However, the prevalence rate of Hepatitis B 
contamination in overall population of Iran has declined since 
1977, but it has still been the most common cause of cirrhosis 
and hepatocellular carcinoma in Iran (3). 
Hepatitis is a medical condition which is defined by the 
inflammation of the liver and characterized by the presence of 
inflammatory cells in the parenchyma of the organ. Hepatitis 
may occur with poor signs or asymptomatically but often leads 
to jaundice, anorexia, and malaise (4). Hepatitis is known as 
acute when its involvement lasts less than six months; 
however, its chronic form happens when the involvement 
persists longer than six months. Hepatitis viruses are the most 
common cause of this condition all over the world, but 
hepatitis can be caused by other elements typified by toxic 
substances (notably alcohol, certain medications, some 
industrial organic solvents, and plants) and autoimmune 
diseases. Excessive alcohol consumption is an important cause 
of hepatitis and liver damage (cirrhosis). Alcoholic hepatitis 
usually develops over long lasting exposure to alcohol.  
 
 
Alcohol intake over than 80 grams per day in men and 40 
grams per day in women has been associated with the 
development of alcoholic hepatitis. The combination of HBV 
contamination and alcohol consumption accelerate the 
development of the cirrhosis (5). 
In 1992, WHO made recommendation to consider Hepatitis 
B vaccine in the national immunization programs in all highly 
endemic countries by 1995 and all other countries by 1997 (1). 
The early and first licensed Hepatitis B vaccines were plasma-
derived, which were built of purified HBsAg. In endemic 
countries, 80% of all the vaccines designed are almost plasma-
derived (6). However, the commonly available Hepatitis B 
vaccines nowadays are produced by recombinant DNA 
technology (7). The currently used vaccine in Iran is a 
recombinant vaccine which is produced by cloning the S gene, 
encoding the HBsAg of virus. This vaccine is typically 
injected in 3 doses of 20 µg at 0, 1, and 6 months. 
Without intervention, 15-40% of the chronic HBV 
contaminated individuals will develop cirrhosis, end-stage 
liver disease, hepatocellular carcinoma (HCC), or will 
require liver transplantation (8). Screening based upon 
Hepatitis B surface antigen (HBsAg), Hepatitis B core 
antibody (HBcAb), and Hepatitis B surface antibody 
(HBsAb) are recommended for surveying at risk individuals, 
and detection is suggested in order to ensure early diagnosis 
for treatment and monitoring (9). Because of reduction in 
anti-HBs level over the time, Infectious Disease Society of 
America (IDSA) recommends to measure HBs antibody 
Immune Response towards Hepatitis B Virus Vaccination 
 
Infect Epidemiol Med. 2016; Volume 2, Issue 4: 24-28 25 
levels in all high risk cases after administration of three 
doses of Hepatitis B vaccine (10). 
 
2. Objectives 
The aim of this study was to evaluate the post Hepatitis B 
vaccination immune response among medical students of 
Ardabil University of Medical Sciences. Moreover, the effects 
of behavior and lifestyle of participants were assessed on the 
quality of antibody response. 
 
3. Materials and Methods 
3.1. Study subjects 
A total of 219 cases were recruited from medical students 
of Ardabil University of Medical Sciences, Ardabil, Iran over 
2013 and 2015. Students were vaccinated in three doses at the 
times of zero, one and six months. At the time of sampling for 
the study, participants were experiencing less than 5 years 
since the first dose of their vaccination. But in 7 participants, it 
had taken more than 5 years since the first dose of their 
vaccination. Individuals had received no immunomodulatory 
therapy for at least 3 months before they were included in the 
study. The Human Research Ethics Committees from the 
Ardabil University of Medical Sciences approved this study. 
Written informed consent was taken from all the participants. 
About 10 mL blood of each subject was collected in EDTA-
anticoagulated tubes using venipuncture. 
 
3.2. Questionnaire form 
A questionnaire was designed containing questions about 
susceptibility factors which possibly change the immunologic 
response such as alcohol consumption and the lasted time 
since last vaccination. 
3.3. Preparation of samples 
From 5 mLvenous blood of each volunteer, serums were 
collected through centrifugation at 3000 rpm. The serum 
samples were then sent to paraclinical laboratory of Imam 
Khomeini hospital in Ardabil city for further examinations, 
namely ELISA. 
3.4. HBsAg and HBsAb titration measurement via ELISA 
Samples were tested for anti-HBs antibody to gain titers of 
the antibody against HBsAg in order to detect immune 
response. ELISA test was applied to evaluate the levels of 
HBsAb and HBsAg in serum samples. Human Anti-Hepatitis 
B Surface Antigen IgG (anti-HBsAb-IgG) ELISA kit (Cat# 
4200; Alpha Diagnostic Intl Inc., San Antonio, TX 78244, 
USA) for the measurement of anti-HBsAb after vaccination 
was applied according the manufacture’s manuals. After 
determination of the antibody titer, these titers were 
categorized into four range groups according to the guidelines 
as follow: Group I: Non- responders (Titer<10 mIU.mL-1); 
Group II: Low-responders (10≤ Titer <100 mIU.mL-1); Group 
III: Appropriate-responders (Titer100≤Titer<1000 mIU.mL-1); 
Group IV: Excellent-responders (Titer≥1000 mIU.mL-1). 
Antibody titration levels ≥10 mIU.mL-1 were considered as 
acceptable immune response and those levels of<10 mIU.mL-1 
were not acceptable. In cases in which the antibody responses 
were not acceptable, HBsAg titers were detected using 
Hepatitis B Surface Antigen (HBs-Ag, native or recombinant) 
ELISA Kit (Cat# 4110; Alpha Diagnostic Intl Inc., San 
Antonio, TX 78244, USA). 
 
3.5. Statistical analysis 
Data analysis was conducted using SPSS software version 
21 (SPSS, Chicago, IL, USA). Scale variables were calculated 
for normality of distribution using the Kolmogorov–Smirnov 
test. By using the independent sample t-test, comparing the 
continuous variables of the groups were carried out. If the 
variables were not normally distributed, Mann-Whitney 
nonparametric test was conducted. To depict data by graphs, 
the GraphPad Prism version 5.00 for Windows (GraphPad 
Software, La Jolla California USA, www.graphpad.com) was 
used. All results were expressed as mean ± standard deviation 
(SD), and statistical significance was set at 5%. 
 
4. Results 
Of all the 219 participants, 71 cases (32.4%) were male and 
the remaining 148 volunteers (67.6%) were female. Mean age of 
male and female individuals were 22.2±2.7 and 21.3±3.4, 
respectively. Among subjects, 4 (1.8%) and 37 (16.9) cases were 
alcoholic and smoker, respectively. None of the subjects had a 
family history of immune based disease. It was observed that 201 
cases (91.8%) out of 219 cases had positive anti-HBs antibody 
response, and 18 subjects (8.2%) were nonresponsive. 
Among the subjects, 18 individuals (8.2%) were 
categorized into Group I (Non-responders), 36 individuals 
(16.4%) were categorized into Group II (Low- responders), 
146individuals (66.7%) were categorized into Group III 
(Appropriate-responders), and finally 19 individuals (8.7%) 
were categorized into Group IV (Excellent-responders). The 
mean concentration of HBsAb for each group was 5.1±2.3, 
54.66±4.3, 419.31±11.85, 1106.65±48.98, respectively. 
Moreover, none of the non-responder subjects were positive 
for HBsAg. 
The mean antibody titer in males and females were 
395.72±46.33 and 397.33±27.85, respectively. No significant 
difference was observed in antibody concentration between 
males and females (P=0.871; Table 1, Figure 1.A).No 
significant difference was observed in HBsAb titration level 
between smokers and non-smokers (P=0.151; Figure 1.C), 
while alcoholics (215.41±23.52) demonstrated decreased 
HBsAb concentration in comparison to non-alcoholic 
(577.59±41.33) individuals (P<0.001; Figure 1.B). Subjects 
with less than 5 years since the last vaccination (442.75 ± 
21.7) developed significantly (P<0.001; Figure 1.D) more 
levels  of  HBsAb  in  comparison  to  those  with  more  than  5  
years since the last vaccination (350.25 ± 25.4). 
 
Table 1. Comparison of anti-HBs antibody titration among various study groups. 
Variable Number Mean anti-HBs antibody titer(mIU/mL) P-value 
Sex Male 71 (32.4) 395.72 ± 46.33 0.871 Female 148 (67.6) 397.33 ± 27.85 
Alcohol consumption 
Yes 4 (1.8%) 215.41±23.52 
<0.001 
No 215 (98.2%) 577.59±41.33 
Smoking 
Yes 37 (16.9%) 384.55 ± 14.31 
0.151 
No 182 (83.1%) 408.45 ± 34.11 
Time since last vaccination 
>5 years ago 7 (3.2%) 350.25 ± 25.4 
<0.001 <5 years ago 212 (96.8%) 442.75 ± 21.7 
Falah Khoshkholgh E et al. 
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Figure 1. Comparison of antibody titration between various groups of (A) males and females, (B) alcoholics and non-alcoholics, (C) smokers 
and non-smokers, and (D) subjects with less and greater than 5 years since last vaccination. 
 
5. Discussion 
HBV infection is a universal challenging health issue, and 
HBV is one of the oncogenic viruses which are vaccine-
preventable. HBV vaccine induces anti-HBs antibody 
response which can prevent HBV infection. Prevention of 
primary infection by vaccination is an important strategy to 
decrease the risk of chronic HBV infection and its subsequent 
complications. Studies have shown that childhood vaccination 
significantly could reduce the rate of chronic HBV infection 
(11). Medical students are high-risk group to be contaminated 
by HBV(12). 
In our study, 91.8% of the subjects had protective level of 
anti-HBs antibody (Titer≥10 mIU.mL-1). This result is almost 
similar to that of other studies performed globally as well as in 
Iranian adults (12, 13). The standard immune response rate 
towards HBV has been declared approximately 91.3% among 
general population (14). In a study on 89 medical students, 
100% of the subjects had adequate antibody response after 6 
months from the injection of the second dose of HBV vaccine 
(15). 
In this study, it was found that 18 subjects (8.2%) did not 
develop protective antibody response to vaccination. The 
quality and quantity of immune response (Ir) to an antigen, 
which is recognized by T-lymphocytes, is regulated 
genetically, mainly through Major Histocompatibility 
Complex (MHC) associated Ir genes (16). Binding of peptides 
to MHC Class I and II molecules demonstrates a certain status 
of specificity. Some peptides are bound with higher affinity to 
the products of certain alleles, and this differential binding is 
important for the induction or suppression of an immune 
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response to a particular antigen. It has been shown that an 
individual's immune responsiveness to HBV is under genetic 
MHC control, and the course of the infection seems to be 
influenced by one’s HLA phenotype (17, 18). On the other 
hand, human MHC-related Ir genes may be operative in 
regulating the T-dependent humoral antibody and T-cell 
mediated immune response to HBsAg (19). In a study, wide 
application of the HBV vaccination showed that a low 
proportion of the vaccinated people failed to raise protective 
antibodies (20). 
In our study, no difference was observed in HBsAb 
titration between males and females. This observation was in 
accordance with the previous studies (21, 22) in which the 
influence of gender on vaccine response was not seen. 
Moreover, our study demonstrated similar results with Alavian 
et al. (23), as students with longer interval between their last 
vaccination and the first vaccination at the time of the study 
revealed lower level of antibody titration in comparison to 
those who their vaccination had been accomplished less than 
five years before the first vaccination at the time of the study. 
This observation is because of humoral immune system 
responses that had existed previously. Humoral arm of 
adaptive immune system is the specific defense against 
bacteria and viruses that cross through the body fluids. In this 
kind of immunity, the B cells (B lymphocytes) play the main 
role. When B cells respond to the antigen for the first time, 
they are activated, proliferated, and finally differentiated into 
plasma cells and memory B cells. Plasma cells produce and 
secret a protein combination that are called antibody. After the 
first antigen recognition, memory B cells also recognize the 
same antigen and mostly differentiate to plasma cells, and less 
to memory cells, resulting in further antibody production in 
larger amounts and more velocity (24). 
The HBsAb titration was not significantly different 
between smoker and non-smoker subjects. However, 
nonalcoholics had developed powerful antibody response 
against vaccination. Cigarette smoking, heavy alcohol 
consumption, and HBsAg have been independently associated 
with increased risk of mortality from hepatocellular carcinoma 
(25). A number of studies has previously reported an 
association between Hepatitis B viral infection and alcohol 
consumption (26, 27). A randomized double-blind trial has 
evaluated the efficacy of a high-dose versus standard-dose 
Hepatitis B vaccine in alcoholic individuals. It has been 
reported that high- and accelerated-dose regimen of Hepatitis 
B vaccination leads to the improvements in the immune 
response in alcoholic individuals (28). 
There are limitations in this study that need to be 
addressed; the effect of alcohol consumption on the quality 
and quantity of immune response against vaccine is dose-
dependent. We did not have information about the dose of 
alcohol intake in the alcoholic cases of study subjects. Hence, 
we conclusively report that nonalcoholics had developed high-
quantity response against vaccination compared with alcoholic 
subjects. Furthermore, considering the little number of 
alcoholic cases in our study subjects, we could not conclude 
strongly about the impression underlying alcohol intake on the 
development of antibody response. 
 
6. Conclusion 
The results of the present study show that immunogenicity 
to HBV is not perfect and decreases with the progression of 
time lasting from the third dose of vaccination. Alternately, 
alcohol intake significantly reduces the quantity of antibody 
response. According to the results, we suggest that the anti-
HBs antibody evaluation to be conducted after the completion 
of vaccination program to ensure the attainment of adequate 
protective antibody levels. It would be useful for management 
of health policy and programs, although conducting other 
studies will be necessary to reach to the vigorous conclusions 
in Iranian population. 
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